Literature DB >> 31960533

Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame.

Dominika A Kalkowska1, Mark A Pallansch2, Steven G F Wassilak3, Stephen L Cochi3, Kimberly M Thompson1.   

Abstract

Nearly 20 years after the year 2000 target for global wild poliovirus (WPV) eradication, live polioviruses continue to circulate with all three serotypes posing challenges for the polio endgame. We updated a global differential equation-based poliovirus transmission and stochastic risk model to include programmatic and epidemiological experience through January 2020. We used the model to explore the likely dynamics of poliovirus transmission for 2019-2023, which coincides with a new Global Polio Eradication Initiative Strategic Plan. The model stratifies the global population into 72 blocks, each containing 10 subpopulations of approximately 10.7 million people. Exported viruses go into subpopulations within the same block and within groups of blocks that represent large preferentially mixing geographical areas (e.g., continents). We assign representative World Bank income levels to the blocks along with polio immunization and transmission assumptions, which capture some of the heterogeneity across countries while still focusing on global poliovirus transmission dynamics. We also updated estimates of reintroduction risks using available evidence. The updated model characterizes transmission dynamics and resulting polio cases consistent with the evidence through 2019. Based on recent epidemiological experience and prospective immunization assumptions for the 2019-2023 Strategic Plan, the updated model does not show successful eradication of serotype 1 WPV by 2023 or successful cessation of oral poliovirus vaccine serotype 2-related viruses. Published 2020. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  Dynamic modeling; eradication; polio; poliovirus vaccine

Mesh:

Substances:

Year:  2020        PMID: 31960533      PMCID: PMC7787008          DOI: 10.1111/risa.13447

Source DB:  PubMed          Journal:  Risk Anal        ISSN: 0272-4332            Impact factor:   4.000


  35 in total

1.  Expanded programme on immunization. Poliomyelitis in 1988, 1989, and 1990.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  1992-04-17

Review 2.  Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Konstantin M Chumakov; Neal A Halsey; Tapani Hovi; Philip D Minor; John F Modlin; Peter A Patriarca; Roland W Sutter; Peter F Wright; Steven G F Wassilak; Stephen L Cochi; Jong-Hoon Kim; Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-28       Impact factor: 4.000

3.  Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation.

Authors:  Radboud J Duintjer Tebbens; Lee M Hampton; Steven G F Wassilak; Mark A Pallansch; Stephen L Cochi; Kimberly M Thompson
Journal:  J Vaccines Vaccin       Date:  2016-10-03

4.  Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses.

Authors:  Kimberly M Thompson; Dominika A Kalkowska; Radboud J Duintjer Tebbens
Journal:  Vaccine       Date:  2015-02-18       Impact factor: 3.641

Review 5.  Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication.

Authors:  Mark A McKinlay; Marc S Collett; Jeffrey R Hincks; M Steven Oberste; Mark A Pallansch; Hiromasa Okayasu; Roland W Sutter; John F Modlin; Walter R Dowdle
Journal:  J Infect Dis       Date:  2014-11-01       Impact factor: 5.226

6.  Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model.

Authors:  Marc S Collett; Jeffrey R Hincks; Kimberley Benschop; Erwin Duizer; Harrie van der Avoort; Eric Rhoden; Hongmei Liu; M Steven Oberste; Mark A McKinlay; Marianne Hartford
Journal:  J Infect Dis       Date:  2017-02-01       Impact factor: 5.226

Review 7.  Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.

Authors:  Radboud J Duintjer Tebbens; Kimberly M Thompson
Journal:  Expert Rev Vaccines       Date:  2018-08-09       Impact factor: 5.217

8.  Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters.

Authors:  D A Kalkowska; M A Pallansch; K M Thompson
Journal:  Epidemiol Infect       Date:  2019-10-24       Impact factor: 2.451

9.  Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Kimberly M Thompson
Journal:  BMC Infect Dis       Date:  2015-09-17       Impact factor: 3.090

10.  Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Steven G F Wassilak; Stephen L Cochi; Kimberly M Thompson
Journal:  BMC Infect Dis       Date:  2016-03-24       Impact factor: 3.090

View more
  12 in total

1.  Effect of Population Partitioning on the Probability of Silent Circulation of Poliovirus.

Authors:  Celeste Vallejo; Carl A B Pearson; James S Koopman; Thomas J Hladish
Journal:  Bull Math Biol       Date:  2022-05-04       Impact factor: 3.871

Review 2.  Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart.

Authors:  Dominika A Kalkowska; Mark A Pallansch; Stephen L Cochi; Stephanie D Kovacs; Steven G F Wassilak; Kimberly M Thompson
Journal:  Risk Anal       Date:  2020-07-06       Impact factor: 4.000

3.  Modeling Poliovirus Transmission in Borno and Yobe, Northeast Nigeria.

Authors:  Dominika A Kalkowska; Richard Franka; Jeff Higgins; Stephanie D Kovacs; Joseph C Forbi; Steven G F Wassilak; Mark A Pallansch; Kimberly M Thompson
Journal:  Risk Anal       Date:  2020-04-29       Impact factor: 4.000

4.  Modeling Undetected Live Poliovirus Circulation After Apparent Interruption of Transmission: Borno and Yobe in Northeast Nigeria.

Authors:  Dominika A Kalkowska; Kimberly M Thompson
Journal:  Risk Anal       Date:  2020-04-29       Impact factor: 4.000

5.  Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019-2029.

Authors:  Dominika A Kalkowska; Kimberly M Thompson
Journal:  Risk Anal       Date:  2021-02       Impact factor: 4.000

6.  Insights From Modeling Preventive Supplemental Immunization Activities as a Strategy to Eliminate Wild Poliovirus Transmission in Pakistan and Afghanistan.

Authors:  Dominika A Kalkowska; Kimberly M Thompson
Journal:  Risk Anal       Date:  2020-03-06       Impact factor: 4.000

7.  Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain.

Authors:  Dominika A Kalkowska; Mark A Pallansch; Amanda Wilkinson; Ananda S Bandyopadhyay; Jennifer L Konopka-Anstadt; Cara C Burns; M Steven Oberste; Steven G F Wassilak; Kamran Badizadegan; Kimberly M Thompson
Journal:  Risk Anal       Date:  2020-11-10       Impact factor: 4.000

8.  Modeling Poliovirus Surveillance and Immunization Campaign Quality Monitoring Costs for Pakistan and Afghanistan for 2019-2023.

Authors:  Dominika A Kalkowska; Mark A Pallansch; Stephen L Cochi; Kimberly M Thompson
Journal:  Open Forum Infect Dis       Date:  2021-05-23       Impact factor: 3.835

Review 9.  Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.

Authors:  Kimberly M Thompson; Dominika A Kalkowska
Journal:  Risk Anal       Date:  2020-04-27       Impact factor: 4.000

Review 10.  Gastrointestinal and Hepatic Involvement in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Review.

Authors:  Uday C Ghoshal; Ujjala Ghoshal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2020-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.